These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 32586650)
1. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis. Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650 [TBL] [Abstract][Full Text] [Related]
2. Long-term Experience with Anti-tumor Necrosis factor - α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis. Corredores Dieb J; Vofo B; Amer R Ocul Immunol Inflamm; 2024 Aug; 32(6):932-939. PubMed ID: 36538811 [TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077 [TBL] [Abstract][Full Text] [Related]
5. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764 [TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602 [TBL] [Abstract][Full Text] [Related]
8. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. Ashkenazy N; Saboo US; Abraham A; Ronconi C; Cao JH J AAPOS; 2019 Jun; 23(3):151.e1-151.e5. PubMed ID: 31063811 [TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830 [TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669 [TBL] [Abstract][Full Text] [Related]
13. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278 [No Abstract] [Full Text] [Related]
15. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients. Mercier AE; Ribeiro E; Korobelnik JF; Delyfer MN; Rougier MB Ocul Immunol Inflamm; 2018; 26(3):477-484. PubMed ID: 27775458 [TBL] [Abstract][Full Text] [Related]
18. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849 [TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan. Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis]. Zlatanović G; Jovanović S; Veselinović D; Zivković M Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]